News

Biocom California sees India on life sciences radar with its manufacturing prowess and scientific acumen

Biocom California, the leading advocate for life science industry growth worldwide, sees Indian biotech companies cannot be ignored at this point. This is because the country is on the life sciences radar for global companies because of its manufacturing prowess and scientific acumen.

Joseph Panetta, president & CEO, Biocom California said, “It is India’s infrastructure for manufacture of biologics, biosimilars, qualified pool of scientific human resources and strong intellectual property rights’ (IPR) adherence that have been the three top attractive factors for us to be here and scout for potential opportunities in collaborations. Therefore, we are here to understand the industry, market prospects and engage in discussions with Indian biotech companies.

Panetta was in India and Bengaluru to look at potential partnerships and technology transfers for a slew of promising medicines and look for contract research and manufacturing services (CRAMS) besides support with funding for novel drug development initiatives.

We have been watching the Indian life science players closely and wanted to offer them opportunities to scale-up even further. These cover the landscape of early stage innovative therapy companies and CRAMS particularly for biosimilars, he added.

India has already made considerable headway in the area of technologies for life sciences. Here we would look to offload the novel, successful and feasible technologies coming out of our leading universities and research schools in California for possible scale-up to life science established entrepreneurs and start-ups in India. We are already closely looking at our biomedical research possibilities from an India stand point and the investment opportunities as to where to fund if needed. It is also important for investors to understand the biotech business model in India whether they need to fund at the growth stage or scale-up phase, Panetta told Pharmabiz.

Even as oncology, infectious diseases, autoimmune/inflammatory diseases are challenging to treat with no new drugs, Biocom California members of the life science community are eyeing avenues to collaborate in these areas. Specifically infectious diseases in this Covid-19 pandemic phase cannot be ignored. From preventive solutions, vaccines, novel drugs and delivery devices, the offer from our end is comprehensive. Our meetings with Bengaluru-based Anthem Biosciences, Biocon and Syngene have left us impressed with their production plant capacity and advanced manufacturing capability, among others, he said adding that Biocom California team will also visit Hyderabad, India’s life sciences hub.

Infectious diseases research and development is the future and India has its inherent strengths going by the vaccine launches and related new drugs. We will look at the possibilities of disease surveillance, research and development, financing models, supply chain logistic technologies that will give Indian life science sector the faster connect to garner exposure. We are here to explore partnerships that match innovation with investment, said the Biocom California chief.

Besides we are keen to promote a skilled and diverse pipeline of talent pool to accelerate the growth of life science ecosystem where we would be able to send our teams here and vice versa.

India was preferred over China and for that matter any other South East Asian country because of its IP systems in place. We need to get a good sense of the opportunities that exist which were being explored last year. India cannot be ignored as a sizable opportunity to collaborate exists here, said Panetta.

Source: www.pharmabiz.com

Joseph Panetta, president & CEO, Biocom California said, “It is India’s infrastructure for manufacture of biologics, biosimilars, qualified pool of scientific human resources and strong intellectual property rights’ (IPR) adherence that have been the three top attractive factors for us to be here and scout for potential opportunities in collaborations. Therefore, we are here to understand the industry, market prospects and engage in discussions with Indian biotech companies.

Recommended News

Archives